Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Foghorn Therapeutics Inc. (FHTX) reported a Q4 loss of $0.30 per share, missing the Zacks Consensus Estimate of a $0.29 loss. This is an improvement from the $0.57 loss per share a year ago.
March 07, 2025 | 12:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Foghorn Therapeutics reported a Q4 loss of $0.30 per share, slightly missing the consensus estimate of $0.29. Despite the miss, the loss is an improvement from the previous year's $0.57 per share.
The slight miss on earnings estimates is likely to have a negative short-term impact on FHTX's stock price. However, the improvement from last year's loss may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100